This suggest that a series of different events and factors may converge to trigger deregulated JAK/STAT signaling in malignant T cells highlighting the key role of JAK3 and downstream effectors in carcinogenesis in CTCL and other T cell malignancies [26,27,28]. The gene discussed is JAK3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.